SCHEMBL4580889

SCHEMBL4580889

Cc1ccc(Nc2cncc3ccc(C(=O)NCc4ccco4)nc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
LMNA P02545 1/20 0.59
MAPK1 P28482 1/20 0.59
TDP1 Q9NUW8 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
HTT P42858 1/20 0.50
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.47
POLB P06746 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ESR1 P03372 1/20 0.44
PKM P14618 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PYGM P11217 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4579023 0.91 ALDH1A1 (0.50) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4580503 0.90 ALDH1A1 (0.52) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4581518 0.90 MAPT (0.61) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4580584 0.88 GAA (0.48) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4581576 0.86 ALDH1A1 (0.53) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4580266 0.82 POLB (0.53) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL4581196 0.82 ALDH1A1 (0.60) MAPTLMNAMAPK1TDP1SMN1; SMN2
SCHEMBL14266821 0.79 ALDH1A1 (0.55) MAPTTDP1SMN1; SMN2RAB9ANPC1
SCHEMBL5148147 0.78 ALDH1A1 (0.52) MAPTMAPK1TDP1SMN1; SMN2NPC1
SCHEMBL4581265 0.77 ALDH1A1 (0.53) MAPTLMNATDP1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 MAPT 4199/4885LMNA 1779/4885MAPK1 1193/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 MAPT 4199/4885LMNA 1779/4885MAPK1 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.